Fmr LLC maintained its position in shares of Genocea Biosciences Inc (NASDAQ:GNCA) during the fourth quarter, Holdings Channel reports. The fund owned 4,256,230 shares of the company’s stock at the end of the fourth quarter. Fmr LLC owned 0.15% of Genocea Biosciences worth $17,536,000 at the end of the most recent quarter.
Separately, Northpointe Capital LLC raised its position in shares of Genocea Biosciences by 90.2% in the third quarter. Northpointe Capital LLC now owns 1,438,286 shares of the company’s stock valued at $7,364,000 after buying an additional 682,269 shares in the last quarter. Institutional investors and hedge funds own 54.62% of the company’s stock.
Genocea Biosciences Inc (NASDAQ:GNCA) opened at 6.09 on Friday. The firm’s market capitalization is $173.22 million. Genocea Biosciences Inc has a one year low of $3.28 and a one year high of $7.49. The stock has a 50 day moving average of $5.28 and a 200 day moving average of $4.59.
Several equities analysts have recently commented on GNCA shares. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Wednesday, January 4th. Cowen and Company set a $40.00 price objective on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Wednesday, December 14th. FBR & Co restated an “outperform” rating on shares of Genocea Biosciences in a report on Monday, January 23rd. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a report on Friday, December 16th. Finally, Vetr lowered shares of Genocea Biosciences from a “strong-buy” rating to a “buy” rating and set a $5.12 price objective on the stock. in a report on Monday, December 19th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $15.65.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a clinical-stage biotechnology company. The Company is a biopharmaceutical company that discovers and develops vaccines and immunotherapies. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences Inc (NASDAQ:GNCA).